 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1. Harrison, Harrison's Principles of Internal Medicine. 14 ed. 1998: McGraw Hill.
2. Onion, D., The Little Black Book of Primary Care. 3rd ed. 1998: Blackwell Science.
3. Ganong, W., Review of Medical Physiology. 17 ed. 1995: Lange.
4. Plaitakis, A. and E. Constantakakis, Altered metabolism of excitatory amino acids, N-acetyl-aspartate and N-acetyl-aspartyl-glutamate in amyotrophic lateral sclerosis. Brain Research Bulletin, 1993. 30(3-4): p. 381-6.
5. Ronzio, R., Naturally Occuring Antioxidants, in Textbook of Naturopathic Medicine, M. Pizorrno, Editor. 1985. p. V:Antiox-1.
6. Jenner, P., Oxidative damage in neurodegenerative disease. Lancet, 1994. 344: p. 796-8.
7. Beal, M., Mitochondria, NO and neurodegeneration. Biochem Soc Symp, 1999. 66: p. 43-54.
8. Beal, M.F., Mitochondria, free radicals, and neurodegeneration. Curr Opin Neurobiol, 1996. 6(5): p. 661-6.
9. Beal, M.F., Mitochondria and the pathogenesis of ALS. Brain, 2000. 123(Pt 7): p. 1291-2.
10. Manfredi, G. and M.F. Beal, The role of mitochondria in the pathogenesis of neurodegenerative diseases. Brain Pathol, 2000. 10(3): p. 462-72.
11. Murphy, A.N., G. Fiskum, and M.F. Beal, Mitochondria in neurodegeneration: bioenergetic function in cell life and death. J Cereb Blood Flow Metab, 1999. 19(3): p. 231-45.
12. Niebroj-Dobosz, I., et al., Anti-neural antibodies in serum and cerebrospinal fluid of amyotrophic lateral sclerosis (ALS) patients. Acta Neurol Scand, 1999. 100(4): p. 238-43.
13. Pestronk, A., et al., Serum antibodies to GM1 ganglioside in amyotrophic lateral sclerosis. Neurology, 1988. 38(9): p. 1457-61.
14. Pestronk, A., et al., A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol, 1988. 24(1): p. 73-8.
15. Pestronk, A., et al., Patterns of serum IgM antibodies to GM1 and GD1a gangliosides in amyotrophic lateral sclerosis. Ann Neurol, 1989. 25(1): p. 98-102.
16. Appel, S.H., et al., Amyotrophic lateral sclerosis. Associated clinical disorders and immunological evaluations. Arch Neurol, 1986. 43(3): p. 234-8.
17. Salazar-Grueso, E.F. and R.P. Roos, Amyotrophic lateral sclerosis and viruses. Clin Neurosci, 1995. 3(6): p. 360-7.
18. Racek, J., et al., [Free radicals in immunology and infectious diseases]. Epidemiol Mikrobiol Imunol, 2001. 50(2): p. 87-91.
19. Garcia-Moreno, J.M., et al., [Neuroborreliosis in a patient with progressive supranuclear paralysis. An association or the cause?]. Rev Neurol, 1997. 25(148): p. 1919-21.
20. Cruz Martinez, A., M. Lara, and C. Villoslada, [Peripheral neuropathy in HIV infection]. Arch Neurobiol (Madr), 1989. 52(Suppl 1): p. 79-92.
21. Dalakas, M.C. and G.H. Pezeshkpour, Neuromuscular diseases associated with human immunodeficiency virus infection. Ann Neurol, 1988. 23(Suppl): p. S38-48.
22. McGuire, V., et al., Occupational exposures and amyotrophic lateral sclerosis. A population-based case-control study. Am J Epidemiol, 1997. 145(12): p. 1076-88.
23. Baker, B., ALS tied to agricultural chemical exposure at work: Strongest link in men exposed under aged 40, in Family Practice News. 1996. p. 1-2.
24. Ames, R.G., et al., Chronic neurologic sequelae to cholinesterase inhibition among agricultural pesticide applicators. Arch Environ Health, 1995. 50(6): p. 440-4.
25. Keifer, M.C. and R.K. Mahurin, Chronic neurologic effects of pesticide overexposure. Occup Med, 1997. 12(2): p. 291-304.
26. Prazmo, A., [Neurologic manifestations in the course of pesticide intoxication]. Neurol Neurochir Pol, 1978. 12(3): p. 327-31.
27. Smith, T.C., G.C. Gray, and J.D. Knoke, Is systemic lupus erythematosus, amyotrophic lateral sclerosis, or fibromyalgia associated with Persian Gulf War service? An examination of Department of Defense hospitalization data. Am J Epidemiol, 2000. 151(11): p. 1053-9.
28. Adams, C.R., D.K. Ziegler, and J.T. Lin, Mercury intoxication simulating amyotrophic lateral sclerosis. Jama, 1983. 250(5): p. 642-3.
29. Armon, C., et al., Epidemiologic correlates of sporadic amyotrophic lateral sclerosis. Neurology, 1991. 41(7): p. 1077-84.
30. Conradi, S., L.O. Ronnevi, and O. Vesterberg, Abnormal tissue distribution of lead in amyotrophic lateral sclerosis. J Neurol Sci, 1976. 29(2-4): p. 259-65.
31. Schwarz, S., et al., Amyotrophic lateral sclerosis after accidental injection of mercury. J Neurol Neurosurg Psychiatry, 1996. 60(6): p. 698.
32. Mano, Y., et al., Mercury in hair of patients with ALS. Rinsho Shinkeigaku, 1989. 29(7): p. 844-8.
33. Mano, Y., et al., Amyotrophic lateral sclerosis and mercury--preliminary report. Rinsho Shinkeigaku, 1990. 30(11): p. 1275-7.
34. Khare, S.S., et al., Trace element imbalances in amyotrophic lateral sclerosis. Neurotoxicology, 1990. 11(3): p. 521-32.
35. Garruto, R.M., et al., Intraneuronal deposition of calcium and aluminium in amyotropic lateral sclerosis of Guam. Lancet, 1985. 2(8468): p. 1353.
36. Aschner, M., Manganese: brain transport and emerging research needs. Environ Health Perspect, 2000. 108 Suppl 3: p. 429-32.
37. Aoyama, K., et al., Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases. Ann Neurol, 2000. 47(4): p. 524-7.
38. Van den Bergh, R., et al., Adipose tissue cellularity in patients with amyotrophic lateral sclerosis. Clin Neurol Neurosurg, 1977. 80(4): p. 226-39.
39. Yasui, M., et al., Aluminum deposition in the central nervous system of patients with amyotrophic lateral sclerosis from the Kii Peninsula of Japan. Neurotoxicology, 1991. 12(3): p. 615-20.
40. Yasui, M., et al., High aluminum deposition in the central nervous system of patients with amyotrophic lateral sclerosis from the Kii Peninsula, Japan: two case reports. Neurotoxicology, 1991. 12(2): p. 277-83.
41. Reyes, E.T., et al., Insulin resistance in amyotrophic lateral sclerosis. J Neurol Sci, 1984. 63(3): p. 317-24.
42. Nagano, Y., T. Tsubaki, and T.N. Chase, Endocrinologic regulation of carbohydrate metabolism. Amyotrophic lateral sclerosis and Parkinsonism-dementia on Guam. Arch Neurol, 1979. 36(4): p. 217-20.
43. Hansel, Y., M. Ackerl, and G. Stanek, [ALS-like sequelae in chronic neuroborreliosis]. Wien Med Wochenschr, 1995. 145(7-8): p. 186-8.
44. Roos, R.P., et al., Amyotrophic lateral sclerosis with antecedent poliomyelitis. Arch Neurol, 1980. 37(5): p. 312-3.
45. Eisen, A.A. and A.J. Hudson, Amyotrophic lateral sclerosis: concepts in pathogenesis and etiology. Can J Neurol Sci, 1987. 14(4): p. 649-52.
46. Scelsa, S. and I. Khan, Blood pressure elevations in riluzole-treated patients with amyotrophic lateral sclerosis. Eur Neurol, 2000. 43(4): p. 224-7.
47. Perlmutter, D., BrainRecovery.com. 2000, Naples, FL: The Perlmutter Health Center.
48. Ludolph, A.C. and M.W. Riepe, Do the benefits of currently available treatments justify early diagnosis and treatment of amyotrophic lateral sclerosis? Arguments against. Neurology, 1999. 53(8): p. S46-9; discussion S55-7.
49. Rowland, L.P., Controversies about amyotrophic lateral sclerosis. Neurologia, 1996. 11 Suppl 5: p. 72-4.
50. Hurko, O. and F. Walsh, Novel drug development for amyotrophic lateral sclerosis. Neurol Sci, 2000. Nov 1,180(1-2): p. 21-8.
51. Jain, K., et al., Evaluation of memantine for neuroprotection in dementia. Expert Opin Investig Drugs, 2000. 9(6): p. 1397-406.
52. Parsons, C., W. Danysz, and G. Quack, Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptorantagonist -- a review of preclinical data. Neuropharmacology, 1999. 38(6): p. 735-67.
53. Askmark, H., et al., A pilot trial of dextromethorphan in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery & Psychiatry, 1993. 56(2): p. 197-200.
54. Eisen, A. and C. Krieger, Pathogenic mechanisms in sporadic amyotrophic lateral sclerosis. Canadian Journal of Neurological Sciences, 1993. 20(4): p. 286-96.
55. Torres-Aleman, I., V. Barrios, and J. Berciano, The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis. Neurology, 1998. 50(3): p. 772-6.
56. Dore, S., et al., Distribution and levels of insulin-like growth factor (IGF-I and IGF- II) and insulin receptor binding sites in the spinal cords of amyotrophic lateral sclerosis (ALS) patients. Brain Res Mol Brain Res, 1996. 41(1-2): p. 128-33.
57. Lewis, M.E., et al., Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Experimental Neurology, 1993. 124(1): p. 73-88.
58. Ackerman, S.J., et al., Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS. Pharmacoeconomics, 1999. 15(2): p. 179-95.
59. Lai, E.C., et al., Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology, 1997. 49(6): p. 1621-30.
60. Lange, D.J., et al., Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. North American ALS/IGF-I Study Group. Neurology, 1996. 47(4 Suppl 2): p. S93-4; discussion S94-5.
61. Borasio, G.D., et al., A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology, 1998. 51(2): p. 583-6.
62. Lorigados, L., et al., [Nerve growth factor and neurological diseases]. Rev Neurol, 1998. 26(153): p. 744-8.
63. Kurek, J.B., et al., LIF (AM424), a promising growth factor for the treatment of ALS. J Neurol Sci, 1998. 160 Suppl 1: p. S106-13.
64. Lindsay, R.M., Neurotrophic growth factors and neurodegenerative diseases: therapeutic potential of the neurotrophins and ciliary neurotrophic factor. Neurobiol Aging, 1994. 15(2): p. 249-51.
65. Bilak, M.M., et al., Neuroprotective utility and neurotrophic action of neurturin in postnatal motor neurons: comparison with GDNF and persephin. Mol Cell Neurosci, 1999. 13(5): p. 326-36.
66. Miller, R.J. and C.W. Ragsdale, Transforming growth factor-beta: death takes a holiday. Nat Neurosci, 2000. 3(11): p. 1061-2.
67. Krieglstein, K., et al., Reduction of endogenous transforming growth factors beta prevents ontogenetic neuron death. Nat Neurosci, 2000. 3(11): p. 1085-90.
68. Lange, D.J., et al., Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol, 1998. 55(1): p. 93-6.
69. Kuhn, W. and T. Muller, The clinical potential of Deprenyl in neurologic and psychiatric disorders. J Neural Transm Suppl, 1996. 48: p. 85-93.
70. Szczudlik, A., et al., [Assessment of the efficacy of treatment with pimozide in patients with amyotrophic lateral sclerosis. Introductory notes]. Neurol Neurochir Pol, 1998. 32(4): p. 821-9.
71. Taylor, C.P., Mechanisms of action of gabapentin. Rev Neurol (Paris), 1997. 153(Suppl 1): p. S39-45.
72. Taylor, C.P., et al., A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res, 1998. 29(3): p. 233-49.
73. Miller, R.G., et al., Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology, 2001. 56(7): p. 843-8.
74. Nelson, L., et al., Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. II. Diet. Am J Epidemiol, 2000. Jan 15;151(2): p. 164-73.
75. Akaike, A., et al., Protective effects of a vitamin B12 analog, methylcobalamin, against glutamate cytotoxicity in cultured cortical neurons. Eur J Pharmacol, 1993. 241(1): p. 1-6.
76. Kikuchi, M., et al., Protective effects of methylcobalamin, a vitamin B12 analog, against glutamate-induced neurotoxicity in retinal cell culture. Invest Ophthalmol Vis Sci, 1997. 38(5): p. 848-54.
77. Oteiza, P.I., et al., Evaluation of antioxidants, protein, and lipid oxidation products in blood from sporadic amyotrophic lateral sclerosis patients. Neurochem Res, 1997. 22(4): p. 535-9.
78. O'Donnell, E. and M.A. Lynch, Dietary antioxidant supplementation reverses age-related neuronal changes. Neurobiol Aging, 1998. 19(5): p. 461-7.
79. Schulz, J., et al., Glutathione, oxidative stress and neurodegeneration. Eur J Biochem, 2000. Aug;267(16): p. 4904-11.
80. Nakamizo, T., et al., Protection of cultured spinal motor neurons by estradiol. Neuroreport, 2000. Nov 9;11(16): p. 3493-7.
81. Rudnicki, S., Estrogen replacement therapy in women with amyotrophic lateral sclerosis. J Neurol Sci, 1999. Oct 31;169(1-2): p. 126-7.
82. Robberecht, W., Genetics of amyotrophic lateral sclerosis. J Neurol, 2000. Dec;246 Suppl 6: p. 2-6.
83. Ikeda, K., et al., Lecithinized superoxide dismutase retards wobbler mouse motoneuron disease. Neuromuscul Disord, 1995. 5(5): p. 383-90.
84. Kinoshita, M. and K. Ikeda, Treatment with lecithinized superoxide dismutase in amyotrophic lateral sclerosis. No To Shinkei, 1998. 50(7): p. 615-24.
85. Estevez, A., et al., Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science, 1999. Dec 24;286(5449): p. 2498-500.
86. Andreassen, O., et al., N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport, 2000. Aug 3; 11(11): p. 2491-3.
87. Henderson, J.T., et al., Reduction of lower motor neuron degeneration in wobbler mice by N-acetyl-L-cysteine. J Neurosci, 1996. 16(23): p. 7574-82.
88. Vyth, A., et al., Survival in patients with amyotrophic lateral sclerosis, treated with an array of antioxidants. J Neurol Sci, 1996. 139 Suppl: p. 99-103.
89. Kok, A.B., Ascorbate availability and neurodegeneration in amyotrophic lateral sclerosis. Med Hypotheses, 1997. 48(4): p. 281-96.
90. Werbach, M., Neuromuscular Degeneration, in Nutritional Influences on Illness. 1996, Third Line Press. p. 451.
91. Wechsler, I., The treatment of amylotrophic lateral sclerosis with vitamin E (tocopherols). Am J Med Sci, 1940. 200: p. 765-778.
92. Rosenberger, A., Observations on the threatment of amylotropic lateral sclerosis with vitamin E. Med Rec, 1941. 154: p. 97-101.
93. Tohgi, H., et al., alpha-Tocopherol quinone level is remarkably low in the cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Neurosci Lett, 1996. 207(1): p. 5-8.
94. Gurney, M.E., et al., Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol, 1996. 39(2): p. 147-57.
95. Reider, C.R. and G.W. Paulson, Lou Gehrig and amyotrophic lateral sclerosis. Is vitamin E to be revisited? Arch Neurol, 1997. 54(5): p. 527-8.
96. Reljanovic, M., et al., Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res, 1999. 31(3): p. 171-9.
97. Ziegler, D., et al., Treatment of symptomatic diabetic peripheral neuropathy with the anti- oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia, 1995. 38(12): p. 1425-33.
98. Klein, W., Treatment of diabetic neuropathy with oral alpha-lipoic acid. MMW Munch Med Wochenschr, 1975. 117(22): p. 957-8.
99. Murase, K., et al., Stimulation of nerve growth factor synthesis/secretion in mouse astroglial cells by coenzymes. Biochemistry & Molecular Biology International, 1993. 30(4): p. 615-21.
100. Kaji R, e.a., Effect of ultra high-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled study. Muscle Nerve, 1998. 21: p. 1775-8.
101. Kira, J., S. Tobimatsu, and I. Goto, Vitamin B12 metabolism and massive-dose methyl vitamin B12 therapy in Japanese patients with multiple sclerosis. Intern Med, 1994. 33(2): p. 82-6.
102. Yamazaki, K., et al., Methylcobalamin (methyl-B12) promotes regeneration of motor nerve terminals degenerating in anterior gracile muscle of gracile axonal dystrophy (GAD) mutant mouse. Neurosci Lett, 1994. 170(1): p. 195-7.
103. Watanabe, T., et al., Ultra-high dose methylcobalamin promotes nerve regeneration in experimental acrylamide neuropathy. J Neurol Sci, 1994. 122(2): p. 140-3.
104. Unknown, Biogenic pathogenesis of subacute combined degeneration of the spinal cord and brain. Inherited Metabolic Diseases, 1993. 16(4): p. 762-70.
105. Mikhailov, V.V. and V.M. Avakumov, [Mechanism of the effect of methylcobalamin on the recovery of neuromuscular functions in mechanical and toxin denervation]. Farmakol Toksikol, 1983. 46(6): p. 9-12.
106. Yamatsu, K., et al., [Pharmacological studies on degeneration and regeneration of the peripheral nerves. (2) Effects of methylcobalamin on mitosis of Schwann cells and incorporation of labeled amino acid into protein fractions of crushed sciatic nerve in rats]. Nippon Yakurigaku Zasshi, 1976. 72(2): p. 269-78.
107. Yamatsu, K., et al., [Pharmacological studies on degeneration and regeneration of peripheral nerves. (1) Effects of methylcobalamin and cobamide on EMG patterns and loss of muscle weight in rats with crushed sciatic nerve]. Nippon Yakurigaku Zasshi, 1976. 72(2): p. 259-68.
108. Sanjak, M., et al., Physiologic and metabolic response to progressive and prolonged exercise in amyotrophic lateral sclerosis. Neurology, 1987. 37(7): p. 1217-20.
109. Faloon, Pregnenolone: The Memory-Enhancing Hormone, in LE Magazine. 1996.
110. Trieu, V.N. and F.M. Uckun, Genistein is neuroprotective in murine models of familial amyotrophic lateral sclerosis and stroke. Biochem Biophys Res Commun, 1999. 258(3): p. 685-8.
111. Koenig, H.L., W.H. Gong, and P. Pelissier, Role of progesterone in peripheral nerve repair. Rev Reprod, 2000. 5(3): p. 189-99.
112. Matthews, R.T., et al., Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A, 1998. 95(15): p. 8892-7.
113. Beal, M., Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. Biofactors, 1999. 9(2-4): p. 261-6.
114. Molina, J., et al., Serum levels of coenzyme Q10 in patients with amyotrophic lateral sclerosis. J Neural Transm, 2000. 107(8-9): p. 1021-6.
115. Klivenyi, P., et al., Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med, 1999. 5(3): p. 347-50.
116. Walter, M.C., et al., Creatine monohydrate in muscular dystrophies: A double-blind, placebo- controlled clinical study. Neurology, 2000. 54(9): p. 1848-50.
117. Tarnopolsky, M., Potential benefits of creatine monohydrate supplementation in the elderly. Curr Opin Clin Nutr Metab Care, 2000. Nov;3(6): p. 497-502.
118. Andreassen, O.A., et al., Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J Neurochem, 2001. 77(2): p. 383-90.
119. Tarnopolsky, M. and J. Martin, Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology, 1999. 52(4): p. 854-7.
120. Sato, Y., et al., Hypovitaminosis D and decreased bone mineral density in amyotrophic lateral sclerosis. Eur Neurol, 1997. 37(4): p. 225-9.
121. Yanagihara, R., et al., Calcium and vitamin D metabolism in Guamanian Chamorros with amyotrophic lateral sclerosis and parkinsonism-dementia. Ann Neurol, 1984. 15(1): p. 42-8.
122. Dean, W., Growth Hormone B. Vitamin Research Newsletter, 2000.
123. Weiner, L.P., Possible role of androgen receptors in amyotrophic lateral sclerosis. A hypothesis. Arch Neurol, 1980. 37(3): p. 129-31.
124. Jones, T.M., R. Yu, and J.P. Antel, Response of patients with amyotrophic lateral sclerosis to testosterone therapy: endocrine evaluation. Arch Neurol, 1982. 39(11): p. 721-2.
125. Poloni, M., et al., Thiamin monophosphate in the CSF of patients with amyotrophic lateral sclerosis. Arch Neurol, 1982. 39(8): p. 507-9.
126. Poloni, M., et al., Inversion of T/TMP ratio in ALS: a specific finding? Ital J Neurol Sci, 1986. 7(3): p. 333-5.
127. Laforenza, U., et al., Thiamin mono- and pyrophosphatase activities from brain homogenate of Guamanian amyotrophic lateral sclerosis and parkinsonism-dementia patients. J Neurol Sci, 1992. 109(2): p. 156-61.
128. Jiang, F., S. DeSilva, and Turnbull, Beneficial effect of ginseng root in SOD-1 (G93A) transgenic mice. J Neurol Sci, 2000. 180(1-2): p. 52-4.
129. Anonymous, Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? The Italian ALS Study Group [see comments]. Neurology, 1993. 43(12): p. 2466-70.
130. Dean, W., Hydergine. 1999.
131. Sozmen, E.Y., et al., Possible supportive effects of co-dergocrine mesylate on antioxidant enzyme systems in aged rat brain. Eur Neuropsychopharmacol, 1998. 8(1): p. 13-6.
132. Faloon, W., Staying Mentally Sharp, A New Study Preventing Mental Incapacity with Hydergine, in LE Magazine. 1998.
133. Vamosi, B., et al., Comparative study of the effect of ethyl apovincaminate and xantinol nicotinate in cerebrovascular diseases. Immediate drug effects on the concentrations of carbohydrate metabolites and electrolytes in blood and CSF. Arzneimittelforschung, 1976. 26(10a): p. 1980-4.
134. Solti, F., M. Iskum, and E. Czako, Effect of ethyl apovincaminate on the cerebral circulation. Studies in patients with obliterative cerebral arterial disease. Arzneimittelforschung, 1976. 26(10a): p. 1945-7.
135. Szobor, A. and M. Klein, Ethyl apovincaminate therapy in neurovascular diseases. Arzneimittelforschung, 1976. 26(10a): p. 1984-9.
136. Biro, K., E. Karpati, and L. Szporny, Protective activity of ethyl apovincaminate on ischaemic anoxia of the brain. Arzneimittelforschung, 1976. 26(10a): p. 1918-20.
137. Faloon, W., Staying Mentally Sharp, Vinpocetine, Life Extension Magazine. 1998.
© 2002
NaturDoctor.com